What are the differences between cefazolin and ceftriaxone?

Cefazolin vs Ceftriaxone: Key Differences

Cefazolin is a first-generation cephalosporin with narrower spectrum but excellent activity against common Gram-positive cocci and select Gram-negatives, while ceftriaxone is a third-generation cephalosporin with broader spectrum but significantly higher risk of Clostridioides difficile infection and should be reserved for specific indications where cefazolin is inadequate. 1

Spectrum of Activity

Cefazolin (1st generation):

• Primary coverage: Staphylococcus aureus, Streptococcus species (excellent Gram-positive activity)
• Secondary coverage: Escherichia coli, Proteus species, Klebsiella species (select Gram-negatives)
• Limitations: No activity against Pseudomonas, Enterobacter, or atypical pathogens 1

Ceftriaxone (3rd generation):

• Broader Gram-negative coverage: All organisms covered by cefazolin PLUS enhanced activity against Enterobacteriaceae, Haemophilus influenzae, Neisseria species
• Additional coverage: Haemophilus, Neisseria meningitidis, some anaerobes (Bacteroides fragilis)
• Limitations: Weaker anti-staphylococcal activity compared to cefazolin; no Chlamydia coverage 2

Clinical Efficacy Comparison

For MSSA Infections:

Cefazolin is superior to ceftriaxone for methicillin-sensitive Staphylococcus aureus. Pharmacodynamic studies demonstrate that ceftriaxone 1g daily shows poor activity with bacterial growth predicted in 76% of cases, while even 2g daily achieves bactericidal effects in only 17% of patients. In contrast, cefazolin 2g twice daily achieves bactericidal activity in 97% of cases 3. However, recent real-world data shows ceftriaxone may be non-inferior for MSSA bloodstream infections in outpatient settings 4, 5.

For Urinary Tract Infections:

Both agents show high susceptibility rates for common uropathogens (E. coli, Klebsiella, Proteus), with cefazolin at 92.5% and ceftriaxone at 97% susceptibility 6. For uncomplicated UTI, cefazolin is non-inferior to ceftriaxone 7, making it the preferred choice given lower collateral damage.

For Klebsiella Bacteremia:

Cefazolin is non-inferior to ceftriaxone for antibiotic-susceptible Klebsiella pneumoniae bacteremia (28-day mortality 10.5% vs 7.1%, p=0.403) 8, despite theoretical concerns about SHV-1 β-lactamase inoculum effects.

Dosing & Pharmacokinetics

Cefazolin:

• Standard: 2g IV every 8 hours (for serious infections)
• Surgical prophylaxis: 2g IV single dose (3g if ≥120kg) 1
• Requires multiple daily doses
• Shorter half-life necessitating more frequent administration

Ceftriaxone:

• Standard: 1-2g IV once daily
• Meningitis: 2g IV every 12 hours 9
• Convenience advantage: Once-daily dosing ideal for outpatient parenteral therapy
• Long half-life allows single daily administration 2

Safety & Collateral Damage

Critical Safety Difference:

Ceftriaxone more than doubles the risk of hospital-onset Clostridioides difficile infection compared to cefazolin (0.40% vs 0.15%; adjusted OR 2.44,95% CI 1.25-4.76) 6. Third-generation cephalosporins carry the highest C. difficile risk of any antibiotic class, while first-generation cephalosporins show no statistical risk increase 6.

Additional ceftriaxone concerns:

• Greater selection pressure for ESBL-producing organisms
• Broader spectrum increases antimicrobial resistance risk
• Contains 83mg (3.6 mEq) sodium per gram 2

Guideline-Based Recommendations

Cefazolin is the preferred first-line agent for surgical prophylaxis (cesarean delivery, cardiac surgery, abdominal procedures), endorsed by ACOG, CDC, and WHO 1. It provides high tissue penetration, proven reduction in surgical site infections and endometritis, and is cost-effective 1.

Ceftriaxone is specifically indicated for:

• Meningitis (Haemophilus, Neisseria meningitidis, Streptococcus pneumoniae) 2
• Gonorrhea (including penicillinase-producing strains) 2
• Infective endocarditis caused by HACEK organisms 9
• Situations requiring once-daily dosing for outpatient therapy when cefazolin is impractical

Clinical Decision Algorithm

Use Cefazolin when:

• MSSA infections (skin/soft tissue, bone/joint, uncomplicated bacteremia)
• Surgical prophylaxis
• Uncomplicated UTI or pyelonephritis
• Klebsiella bacteremia (if susceptible)
• Patient can accommodate multiple daily doses

Use Ceftriaxone when:

• CNS infections (meningitis)
• Gonorrhea
• HACEK endocarditis
• Outpatient parenteral therapy requiring once-daily dosing
• Documented resistance to cefazolin
• Need for broader Gram-negative coverage (Enterobacter, Serratia)

Common Pitfalls

Avoid reflexive ceftriaxone use for convenience alone. The ease of once-daily dosing must be weighed against increased C. difficile risk and antimicrobial stewardship concerns. For most staphylococcal infections, cefazolin's superior pharmacodynamics outweigh ceftriaxone's dosing convenience 3.

Don't assume ceftriaxone is always "better" because it's third-generation. For MSSA and many common infections, the narrower spectrum of cefazolin is actually advantageous, reducing collateral damage while maintaining excellent efficacy 1, 6.